Literature DB >> 15978592

Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen.

Jin-Hong Chang1, Joel A D Javier, Gene-Yuan Chang, Hailton B Oliveira, Dimitri T Azar.   

Abstract

Several anti-angiogenic factors are derived from proteolytic processing of large molecules including endostatin from type XVIII collagen and angiostatin from plasminogen. In previous studies we showed that neostatin-7, the C-terminal 28kDa endostatin-spanning proteolytic fragment, is generated from the proteolytic action of matrix metalloproteinase matrilysin (MMP)-7 on type XVIII collagen. Now, we report a second member of the neostatin family of proteins, neostatin-14. Given the small quantities of neostatin-7 and -14 generated by the breakdown of naturally occurring collagen XVIII (using MMP-7 and -14, respectively), we used two other approaches to characterize the anti-angiogenic properties of these molecules: murine recombinant neostatin in vitro, and gene therapy. We demonstrate that murine recombinant neostatin-7 inhibits calf pulmonary artery endothelial cell proliferation and that microinjection of neostatin-7 and neostatin-14 naked DNA into the corneal stroma of mice results in significant reduction of basic fibroblast growth factor-induced corneal neovascularization. These results provide supportive evidence of the possible anti-angiogenic effect of neostatins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978592     DOI: 10.1016/j.febslet.2005.05.043

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  34 in total

1.  Corneal epithelial MT1-MMP inhibits vascular endothelial cell proliferation and migration.

Authors:  Dimitri T Azar; Fabio H Casanova; Tatsuya Mimura; Sandeep Jain; Zhongjun Zhou; Kyu Yeon Han; Jin-Hong Chang
Journal:  Cornea       Date:  2010-03       Impact factor: 2.651

Review 2.  Wound healing fibroblasts modulate corneal angiogenic privilege: interplay of basic fibroblast growth factor and matrix metalloproteinases in corneal angiogenesis.

Authors:  Jin-Hong Chang; Kyu Yeon Han; Dimitri T Azar
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

Review 3.  Matrix metalloproteinase control of capillary morphogenesis.

Authors:  Cyrus M Ghajar; Steven C George; Andrew J Putnam
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

4.  Endostatin is a trans-synaptic signal for homeostatic synaptic plasticity.

Authors:  Tingting Wang; Anna G Hauswirth; Amy Tong; Dion K Dickman; Graeme W Davis
Journal:  Neuron       Date:  2014-07-24       Impact factor: 17.173

Review 5.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

Review 6.  Vascular wall extracellular matrix proteins and vascular diseases.

Authors:  Junyan Xu; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2014-07-18

Review 7.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

Review 8.  Wound healing after keratorefractive surgery: review of biological and optical considerations.

Authors:  Dimitri T Azar; Jin-Hong Chang; Kyu Yeon Han
Journal:  Cornea       Date:  2012-11       Impact factor: 2.651

9.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  MMP14 Cleavage of VEGFR1 in the Cornea Leads to a VEGF-Trap Antiangiogenic Effect.

Authors:  Kyu-Yeon Han; Jennifer Dugas-Ford; Hyun Lee; Jin-Hong Chang; Dimitri T Azar
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.